http://purl.org/np/RAt6pfYmUI... RAt6pfYmUI

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#wasAttributedTo wasAttributedTo

https://orcid.org/0000-0002-3668-2627 Elif Ozkan

Elif Ozkan

2022-10-13T13:05:17.366Z

http://purl.org/np/RAt6pfYmUI... RAt6pfYmUI

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#generatedAtTime generatedAtTime

2022-10-13T13:05:17.366019

Elif Ozkan

2022-10-13T13:05:17.366Z

http://purl.org/np/RAt6pfYmUI... RAt6pfYmUI

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#wasQuotedFrom wasQuotedFrom

Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors. May be used as first line agent to delay progression of diabetic nephropathy. May also be used to treat uncomplicated hypertension and left ventricular hypertrophy.

Elif Ozkan

2022-10-13T13:05:17.366Z